This administration regimen of a STING inhibitor at disease initiation provides hope that early intervention in patients could also provide a significant delay in neurodegeneration and highlights the translational potential of targeting this pathway in ALS. This evidence concerns the gene STING1 and amyotrophic lateral sclerosis.